Company and Competitor Profile: KBP Biosciences
Overview
KBP Biosciences is a global, clinical-stage biopharmaceutical company, established in 2007, headquartered in New Jersey, USA. The company is focused on researching and developing innovative drugs to address unmet medical needs in cardiovascular, respiratory, inflammatory, and autoimmune diseases. Their dedication is towards transforming advanced biotechnological research into therapies for conditions lacking sufficient treatment options.
Leadership Team
- Bing Li, Ph.D., M.B.A. - Interim Chief Executive Officer
- Fred Yang, Ph.D. - Chief Development Officer and Senior Vice President
- Julia Yang, M.D., M.B.A. - Chief Operating Officer
- Russ Belden - Interim Chief Commercial Officer
- Vincent J. Benn, Ph.D., M.B.A. - Senior Vice President, Regulatory & Medical Affairs
- Kimberly Miller, MSN, CRNP, MBA - Senior Vice President of Clinical Operations
Business Operations & Developments
KBP Biosciences operates an integrated discovery and development platform that efficiently transitions new therapies from research phases into clinical trials. The company raised $76 million in a Series A funding round, involving investors like SDIC Venture Capital, 3E Bioventures, Advantech Capital Partners, and Bay City Capital.
Noteworthy Transactions
A significant agreement includes a $1.3 billion deal with Novo Nordisk for a hypertension drug, Ocedurenone. A legal dispute currently exists, with Novo Nordisk alleging concealment of clinical data and seeking damages totaling $830 million.
Strategic Focus
KBP Biosciences' drug pipeline targets antimicrobial, cardiovascular, and immunology-based solutions. Current legal challenges may impact future strategic directions, investments, and partnerships.
Contact Information
For further details, visit KBP Biosciences' [website](https://www.kbpbiosciences.com).
Competitor Profiling for KBP Biosciences
Key Competitors
APEIRON Biologics
Based in Vienna, Austria, APEIRON Biologics specializes in cancer immunotherapies and therapies for respiratory diseases. Known for the cancer-drug Qarziba®, approved in 2017, the company underwent restructuring in January 2022, transferring R&D activities to invIOs GmbH.
- Leadership:
- Peter Llewellyn-Davies - CEO/CFO
- Romana Gugenberger - CMSO
Edelris
Located in Lyon, France, Edelris is a leading Contract Research Organization (CRO) in drug discovery. They focus on medicinal chemistry and chemical synthesis and provide services to pharmaceutical, biotech, crop protection, and cosmetics sectors. Their innovative solutions include the Keymical Collections™ and Edelris Discovery ENgine (EDEN).
SciVision Biotech
SciVision Biotech, based in Kaohsiung, Taiwan, manufactures and distributes hyaluronic acid medical products. It is listed on the Taiwan Stock Exchange under the stock symbol 1786.TW, and is noted for its vertical integration in production and distribution.
Albachem
Functioning as a trading company within the chemicals sector, Albachem supplies chemicals, petrochemicals, and derivatives globally, maintaining a distinct industry presence.
Strategic Insights
KBP Biosciences contends with rivals like APEIRON Biologics and Edelris. APEIRON focuses on biopharmaceutical innovations, while Edelris excels in drug discovery. SciVision Biotech demonstrates success through vertical integration, posing potential inspiration or partnership avenues for KBP. Understanding these competitive dynamics is essential for KBP to refine its strategic positioning and capitalize on its strengths while enhancing its market presence.
